Xenetic Biosciences Inc. (XBIO)
4.11
0.00 (0.00%)
At close: Jan 15, 2025, 12:29 PM
undefined% (undefined)
| Bid | 3.94 |
| Market Cap | 6.34M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.66 |
| PE Ratio (ttm) | -1.55 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 4.28 |
| Volume | 8,688 |
| Avg. Volume (20D) | 22,277 |
| Open | 4.32 |
| Previous Close | 4.11 |
| Day's Range | 3.93 - 4.32 |
| 52-Week Range | 2.78 - 5.20 |
| Beta | undefined |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2016
Employees 4
Stock Exchange NASDAQ
Ticker Symbol XBIO
Website https://www.xeneticbio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for XBIO stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Xenetic Biosciences Inc. is scheduled to release its earnings on Mar 20, 2025,
after market closes.
Analysts project revenue of $230.00K, reflecting a -65.77% YoY shrinking and earnings per share of -0.2, making a -125.97% decrease YoY.
Analysts project revenue of $230.00K, reflecting a -65.77% YoY shrinking and earnings per share of -0.2, making a -125.97% decrease YoY.
